lundi 16 octobre 2017

Onco Actu du 16 octobre 2017

1. Biologie

Cancer relapse linked to body’s own immune system [Cancer Research UK]

4.1 Dép., diag. & prono. - Prostate

PSA tests aren't great for diagnosing prostate cancer. Here are some better options in the works [LA Times]

5.12 Immunothérapies

Immunotherapy is the newest weapon in the fight against cancer [LA Times]

5.12.2 Immunothérapies - CAR-T

CAR-T therapies are manufactured for each individual patient [Novartis]

New markers could identify patients most at risk of brain damage from CAR T cell immunotherapy [Cancer Research UK]

5.12.8 Immunothérapies - Economie

NICE flip-flops to back Bristol's Opdivo in head and neck cancer despite data 'uncertainties' [FiercePharma]

BMS agrees deal on Opdivo availability through Cancer Drugs Fund for head and neck cancer [Pharmafile]

Hundreds of patients to have access to head and neck cancer drug after new deal, says NICE [NICE]

5.2.3 Pharma - économie

Big Pharma Killed The Cancer Drug He Invented. He Raised $22 Million To Revive It [Forbes]

5.3 Traitements - FDA, EMA, NICE...

EMA Revises Reflection Paper on Pediatric Extrapolation [RAPS]

A Painful, Unacceptable Lack of Data [In the Pipeline]

Little evidence new cancer drugs improve survival [Reuters]

5.3.4 Traitements - AMM (FDA, EMA)

CHMP Issues a Positive Opinion on Janssen’s ZYTIGA® to Include Earlier Stage Prostate Cancer Patients [Janssen]

CHMP recommends EU approval of Roche’s Alecensa (alectinib) as a first-line treatment for people with ALK-positive NSCLC [Roche]

EMA Recommends Extension of Indications for Alectinib [ESMO]

Roche's Alecensa wins EU panel's nod against mutated lung cancer [Reuters]

5.4 Traitements - Economie

Decoding cancer: hopes rise for a new age of precision medicine [Financial Times]

5.9.5 IASLC

AstraZeneca shares its comprehensive scientific approach at the World Conference on Lung Cancer 2017 [AstraZeneca]

6. Lutte contre les cancers

Gains in cancer treatment through the eyes of a survivor [Harvard Gazette]

Rethinking cancer, from the basics to the breakthroughs [LA Times]

Too Many People Dream of a Charmed Life in Academia [Bloomberg]

6.10 Politiques

Nuclear industry acts on 'no deal' Brexit as MPs plot Euratom rebellion [Sky News]

6.12 Ethique

WMA Declaration of Geneva [WMA]

6.9 Controverses

That $1.25B Bristol-Myers IDO1 drug? Incyte claims a former staffer stole it [EndPoints]

Incyte seeks billions after worker allegedly walks off with cancer drug secrets [DelawareOnline]

Cancer drug study data was falsified, says AstraZeneca [The Telegraph]